In the BioHarmony Drug Report Database
Copanlisib
Aliqopa (copanlisib) is a small molecule pharmaceutical. Copanlisib was first approved as Aliqopa on 2017-09-14. It is used to treat follicular lymphoma in the USA. It is known to target phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform, phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform, phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform, serine/threonine-protein kinase mTOR, and phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform. Aliqopa’s patents are valid until 2032-03-29 (FDA).
Trade Name
|
Aliqopa |
|---|---|
Common Name
|
copanlisib |
ChEMBL ID
|
CHEMBL3218576 |
Indication
|
follicular lymphoma |
Drug Class
|
Phosphatidylinositol 3-kinase inhibitors |
Image (chem structure or protein)